MSC-NTF (NurOwn®) exosomes: a novel therapeutic modality in the mouse LPS-induced ARDS model.

Autor: Kaspi H; Brainstorm Cell Therapeutics, Ltd., 1325 Avenue of Americas, New York City, NY, 10019, USA., Semo J; Brainstorm Cell Therapeutics, Ltd., 1325 Avenue of Americas, New York City, NY, 10019, USA., Abramov N; Brainstorm Cell Therapeutics, Ltd., 1325 Avenue of Americas, New York City, NY, 10019, USA., Dekel C; Brainstorm Cell Therapeutics, Ltd., 1325 Avenue of Americas, New York City, NY, 10019, USA., Lindborg S; Brainstorm Cell Therapeutics, Ltd., 1325 Avenue of Americas, New York City, NY, 10019, USA., Kern R; Brainstorm Cell Therapeutics, Ltd., 1325 Avenue of Americas, New York City, NY, 10019, USA., Lebovits C; Brainstorm Cell Therapeutics, Ltd., 1325 Avenue of Americas, New York City, NY, 10019, USA., Aricha R; Brainstorm Cell Therapeutics, Ltd., 1325 Avenue of Americas, New York City, NY, 10019, USA. raricha@brainstorm-cell.com.
Jazyk: angličtina
Zdroj: Stem cell research & therapy [Stem Cell Res Ther] 2021 Jan 19; Vol. 12 (1), pp. 72. Date of Electronic Publication: 2021 Jan 19.
DOI: 10.1186/s13287-021-02143-w
Abstrakt: Background: One of the most severe complications of the current COVID-19 pandemic is acute respiratory distress syndrome (ARDS). ARDS is caused by increased amounts of pro-inflammatory cytokines, leading to lung damage and loss of lung function. There are currently no effective therapies for combatting ARDS. Mesenchymal stem cells (MSCs) have been suggested as a potential treatment for ARDS due to their significant immunomodulatory properties. MSC small extracellular vesicles (sEVs), including exosomes, modulate the immune response as effectively as MSCs themselves, with the added advantages of increased safety and tissue penetration.
Methods: We isolated sEVs from MSCs induced to secrete increased levels of neurotrophic and immunomodulatory factors, termed Exo MSC-NTF, and compared their ability to treat ARDS, in a lung injury LPS mouse model, to sEVs isolated from naïve MSCs (Exo MSC). Measurments of lung histopathological changes and neutrophil infiltration, blood oxygen saturation, and bronchoalveolar lavge fluid (BALF) proinflammatory cytokines and coagulation related factors were performed.
Results: We found that Exo MSC-NTF was superior to Exo MSC in reducing LPS-induced ARDS markers, including physiological lung damage such as alveolar wall thickness, fibrin presence, and neutrophil accumulation, as well as increasing oxygenation levels. Furthermore, Exo MSC-NTF reversed the imbalance in the host immune response, seen as decreased IFN-γ, IL-6, TNF-α, and RANTES levels in the bronchoalveolar lavage fluid.
Conclusions: These positive preclinical results suggest that Exo MSC-NTF may be suitable as a therapy for COVID-19-induced ARDS and are more effective at combatting ARDS physiological, pathological, and biochemical symptoms than sEVs isolated from non-induced MSCs.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje